Clinical Trial: A Phase 2 Study of HB0056 in Patients With Idiopathic Pulmonary Fibrosis

U.S., Nov. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07909655) titled 'A Phase 2 Study of HB0056 in Patients With Idiopathic Pulmonary Fibrosis' on Oct. 27.

Brief Summary: This trial is a 58 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of HB0056, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF.

Study Start Date: Nov., 2026

Study Type: INTERVENTIONAL

Condition: Idiopathic Pulmonary Fibrosis (IPF)

Intervention: DRUG: HB0056

subjects be given HB0056 high dose

DRUG: HB0056

subjects be given HB0056 low dose

DRUG: Placebo

subjects be given placebo during the first...